Structural characterization of the stem-stem dimerization interface between prolactin receptor chains complexed with the natural hormone

Journal of Molecular Biology

Volumn 404, Issue 1, 2010, Pages 112-126

  van Agthoven, Jan ^a,b   Zhang, Chi ^b,c   Tallet, Estelle ^b,c   Raynal, Bertrand ^d,e   Hoos, Sylviane ^d,e   Baron, Bruno ^d,e   England, Patrick ^d,e   Goffin, Vincent ^b,c   Broutin, Isabelle ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSERM   (France)

^d INSTITUT PASTEUR   (France)

^e CNRS   (France)

Author keywords

Growth hormone; Prolactin; Receptor dimerization; Structure; Surface plasmon resonance

Indexed keywords

PHENYLALANINE; PROLACTIN; PROLACTIN RECEPTOR; THREONINE;

ARTICLE; DIMERIZATION; GENETIC VARIABILITY; HORMONE RECEPTOR INTERACTION; PRIORITY JOURNAL; PROTEIN STRUCTURE; SITE DIRECTED MUTAGENESIS; STRUCTURE ANALYSIS; X RAY CRYSTALLOGRAPHY;

EID: 78049441033     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2010.09.036     Document Type: Article

References (47)

1. Goffin V., Shiverick K.T., Kelly P.A., Martial J.A. Sequence-function relationships within the expanding family of prolactin, growth hormone, placental lactogen, and related proteins in mammals. Endocr. Rev. 1996, 17:385-410.
2. Ben-Jonathan N., Mershon J.L., Allen D.L., Steinmetz R.W. Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. Endocr. Rev. 1996, 17:639-669.
3. Bole-Feysot C., Goffin V., Edery M., Binart N., Kelly P.A. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr. Rev. 1998, 19:225-268.
4. Ben-Jonathan N., Hugo E.R., Brandebourg T.D., LaPensee C.R. Focus on prolactin as a metabolic hormone. Trends Endocrinol. Metab. 2006, 17:110-116.
5. Clevenger C.V. Role of prolactin/prolactin receptor signaling in human breast cancer. Breast Dis. 2003, 18:75-86.
6. Tworoger S.S., Hankinson S.E. Prolactin and breast cancer risk. Cancer Lett. 2006, 243:160-169.
7. Rose-Hellekant T.A., Arendt L.M., Schroeder M.D., Gilchrist K., Sandgren E.P., Schuler L.A. Prolactin induces ERalpha-positive and ERalpha-negative mammary cancer in transgenic mice. Oncogene 2003, 22:4664-4674.
8. Manhes C., Kayser C., Bertheau P., Kelder B., Kopchick J.J., Kelly P.A., et al. Local over-expression of prolactin in differentiating mouse mammary gland induces functional defects and benign lesions, but no carcinoma. J. Endocrinol. 2006, 190:271-285.
9. Oakes S.R., Robertson F.G., Kench J.G., Gardiner-Garden M., Wand M.P., Green J.E., Ormandy C.J. Loss of mammary epithelial prolactin receptor delays tumor formation by reducing cell proliferation in low-grade preinvasive lesions. Oncogene 2007, 26:543-553.
10. Clevenger C.V., Furth P.A., Hankinson S.E., Schuler L.A. The role of prolactin in mammary carcinoma. Endocr. Rev. 2003, 24:1-27.
11. Dagvadorj A., Collins S., Jomain J.B., Abdulghani J., Karras J., Zellweger T., et al. Autocrine prolactin promotes prostate cancer cell growth via Janus kinase-2-signal transducer and activator of transcription-5a/b signaling pathway. Endocrinology 2007, 148:3089-3101.
12. Goffin V., Bernichtein S., Kayser C., Kelly P.A. Development of new prolactin analogs acting as pure prolactin receptor antagonists. Pituitary 2003, 6:89-95.
13. Tallet E., Rouet V., Jomain J.B., Kelly P.A., Bernichtein S., Goffin V. Rational design of competitive prolactin/growth hormone receptor antagonists. J. Mammary Gland Biol. Neoplasia 2008, 13:105-117.
14. DePalatis L., Almgren C.M., Patmastan J., Troyer M., Woodrich T., Brooks C.L. Structure and function of a new class of human prolactin antagonists. Protein Expression Purif. 2009, 66:121-130.
15. Jomain J.B., Tallet E., Broutin I., Hoos S., van Agthoven J., Ducruix A., et al. Structural and thermodynamic bases for the design of pure prolactin receptor antagonists: X-ray structure of Del1-9-G129R-hPRL. J. Biol. Chem. 2007, 282:33118-33131.
16. Broutin I., Jomain J.B., Tallet E., van Agthoven J., Raynal B., Hoos S., et al. Crystal structure of an affinity-matured prolactin complexed to its dimerized receptor reveals the topology of hormone binding site 2. J. Biol. Chem. 2010, 285:8422-8433.
17. Teilum K., Hoch J.C., Goffin V., Kinet S., Martial J.A., Kragelund B.B. Solution structure of human prolactin. J. Mol. Biol. 2005, 351:810-823.
18. Somers W., Ultsch M., De Vos A.M., Kossiakoff A.A. The X-ray structure of a growth hormone-prolactin receptor complex. Nature 1994, 372:478-481.
19. Goffin V., Bernichtein S., Touraine P., Kelly P.A. Development and potential clinical uses of human prolactin receptor antagonists. Endocr. Rev. 2005, 26:400-422.
20. Gadd S.L., Clevenger C.V. Ligand-independent dimerization of the human prolactin receptor isoforms: functional implications. Mol. Endocrinol. 2006, 20:2734-2746.
21. Qazi A.M., Tsai-Morris C.H., Dufau M.L. Ligand-independent homo- and heterodimerization of human prolactin receptor variants: inhibitory action of the short forms by heterodimerization. Mol. Endocrinol. 2006, 20:1912-1923.
22. Walker A.M. Prolactin receptor antagonists. Curr. Opin. Invest. Drugs 2005, 6:378-385.
23. Brown R.J., Adams J.J., Pelekanos R.A., Wan Y., McKinstry W.J., Palethorpe K., et al. Model for growth hormone receptor activation based on subunit rotation within a receptor dimer. Nat. Struct. Mol. Biol. 2005, 12:814-821.
24. Waters M.J., Hoang H.N., Fairlie D.P., Pelekanos R.A., Brown R.J. New insights into growth hormone action. J. Mol. Endocrinol. 2006, 36:1-7.
25. Rowlinson S.W., Yoshizato H., Barclay J.L., Brooks A.J., Behncken S.N., Kerr L.M., et al. An agonist-induced conformational change in the growth hormone receptor determines the choice of signalling pathway. Nat. Cell Biol. 2008, 10:740-747.
26. Gertler A., Grosclaude J., Strasburger C.J., Nir S., Djiane J. Real-time kinetic measurements of the interactions between lactogenic hormones and prolactin-receptor extracellular domains from several species support the model of hormone-induced transient receptor dimerization. J. Biol. Chem. 1996, 271:24482-24491.
27. Elkins P.A., Christinger H.W., Sandowski Y., Sakal E., Gertler A., de Vos A.M., Kossiakoff A.A. Ternary complex between placental lactogen and the extracellular domain of the prolactin receptor. Nat. Struct. Biol. 2000, 7:808-815.
28. Svensson L.A., Bondensgaard K., Norskov-Lauritsen L., Christensen L., Becker P., Andersen M.D., et al. Crystal structure of a prolactin receptor antagonist bound to the extracellular domain of the prolactin receptor. J. Biol. Chem. 2008, 283:19085-19094.
29. Cunningham B.C., Bass S., Fuh G., Wells J.A. Zinc mediation of the binding of human growth hormone to the human prolactin receptor. Science 1990, 250:1709-1712.
30. Bogorad R.L., Courtillot C., Mestayer C., Bernichtein S., Harutyunyan L., Jomain J.B., et al. Identification of a gain-of-function mutation of the prolactin receptor in women with benign breast tumors. Proc. Natl Acad. Sci. USA 2008, 105:14533-14538.
31. Kossiakoff A.A., Somers W., Ultsch M., Andow K., Muller Y.A., De Vos A.M. Comparison of the intermediate complexes of human growth hormone bound to the human growth hormone and prolactin receptors. Protein Sci. 1994, 3:1697-1705.
32. Syed R.S., Reid S.W., Li C., Cheetham J.C., Aoki K.H., Liu B., et al. Efficiency of signalling through cytokine receptors depends critically on receptor orientation. Nature 1998, 395:511-516.
33. Stauber D.J., Debler E.W., Horton P.A., Smith K.A., Wilson I.A. Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor. Proc. Natl Acad. Sci. USA 2006, 103:2788-2793.
34. Weidemann T., Hofinger S., Muller K., Auer M. Beyond dimerization: a membrane-dependent activation model for interleukin-4 receptor-mediated signalling. J. Mol. Biol. 2007, 366:1365-1373.
35. Wu L., McElheny D., Huang R., Keiderling T.A. Role of tryptophan-tryptophan interactions in Trpzip beta-hairpin formation, structure, and stability. Biochemistry 2009, 48:10362-10371.
36. Bernat B., Pal G., Sun M., Kossiakoff A.A. Determination of the energetics governing the regulatory step in growth hormone-induced receptor homodimerization. Proc. Natl Acad. Sci. USA 2003, 100:952-957.
37. Chen C., Brinkworth R., Waters M.J. The role of receptor dimerization domain residues in growth hormone signaling. J. Biol. Chem. 1997, 272:5133-5140.
38. de Vos A.M., Ultsch M., Kossiakoff A.A. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science 1992, 255:306-312.
39. Schuck P. Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and Lamm equation modeling. Biophys. J. 2000, 78:1606-1619.
40. Garcia De La Torre J., Huertas M.L., Carrasco B. Calculation of hydrodynamic properties of globular proteins from their atomic-level structure. Biophys. J. 2000, 78:719-730.
41. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. Sect. D 1994, 50:760-763. Collaborative Computational Project, Number 4.
42. Potterton E., Briggs P., Turkenburg M., Dodson E. A graphical user interface to the CCP4 program suite. Acta Crystallogr. Sect. D 2003, 59:1131-1137.
43. McCoy A.J., Grosse-Kunstleve R.W., Adams P.D., Winn M.D., Storoni L.C., Read R.J. Phaser crystallographic software. J. Appl. Crystallogr. 2007, 40:658-674.
44. Adams P.D., Afonine P.V., Bunkoczi G., Chen V.B., Davis I.W., Echols N., et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. Sect. D 2010, 66:213-221.
45. Emsley P., Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr. Sect. D 2004, 60:2126-2132.
46. Davis I.W., Leaver-Fay A., Chen V.B., Block J.N., Kapral G.J., Wang X., et al. MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res. 2007, 35:W375-W383.
47. Urzhumtseva L., Afonine P.V., Adams P.D., Urzhumtsev A. Crystallographic model quality at a glance. Acta Crystallogr. Sect. D 2009, 65:297-300.